chapter 7shodhganga.inflibnet.ac.in/bitstream/10603/50384/14/14_reference.pdf · chapter 7...
TRANSCRIPT
Chapter 7
References
REFERENCES
(201)
Abdalla DS, Campa A, Monteiro HP. Low density lipoprotein oxidation by
stimulated neutrophils and ferritin. Atherosclerosis. 1992;97:149-59.
Alderman MH, Uric acid and cardiovascular risk. Curropin Pharmacology.
2002; 2:126-30.
al-Refaie FN, Wickens DG, Wonke B, Kontoghiorghes GJ, Hoffbrand AV.
Serum non-transferrin-bound iron in beta-thalassaemia major patients treated
with desferrioxamine and L1. Brit J Haematol. 1992;82:431-6.
Anderson GJ. Non-transferrin-bound iron and cellular toxicity. J Gastroenterol
Hepatol. 1999;14(2):105-8.
Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM and Pennell DJ.
Comparison of effects of oral deferiprone and subcutaneous desferrioxamine
on myocardial iron concentrations and ventricular function in beta-
thalassaemia. The Lancet. 2002;360 (9332); 516-20.
Andrewsa NC. Disorders of iron metabolism. N Engl J Med. 1999;341:1986-
95.
Andrews NC. The iron transporter DMT 1. Int J Biochem Cell Biol.
1999;31:991-4.
Andrews, NC. Iron homeostasis: insights from genetics and animal models.
Nat. Rev., Genet. 2000;1:208-17.
Ann Chen Wu, Leann Lesperance, Henry Bernstein. Screening for iron
deficiency, Pediatrics in Review. May 2002;23(5):171-8.
Aruoma OI, Bomford A, Polson RJ, Halliwell B. Nontransferrin-bound iron in
plasma from hemochromatosis patients: Effect of phlebotomy therapy. Blood.
1988;72:1416-9.
Ascherio A, Willett WC, Rimm EB, Giovannucci EL, Stampfer MJ: Dietary
iron intake and risk of coronary disease among men. Circulation. 1994;89:969-
74.
Bacon BR, Britton RS. The pathology of hepatic iron overload: a free
radical—mediated process? Hepatology. 1990; 11: 127-37.
Baer DM, Tekawa IS, Hurley LB: Iron stores are not associated with acute
myocardial infarction. Circulation. 1994;89:2915-8.
Bagdade J, Casaretto A, Albers J. Effects of chronic uremia, hemodialysis and
renal transplantation on plasma lipids and lipoproteins in man. J Lab Clin Med
1976; 87:37-48.
REFERENCES
(202)
Balla G, Jacob HS, Eaton JW, Belcher JD, Vercellotti GM. Hemin: a possible
physiological mediator of low density lipoprotein oxidation and endothelial
injury. Arterioscler Thromb. 1991;11:1700-11.
Batey RG, Lai Chung Fong P, Shamir S, Sherlock S. A non-transferrin-bound
serum iron in idiopathic hemochromatosis. Dig Dis Sci. 1980;25:340-6.
Baykan M, Celik U, Orem A, Malkoc M, Erdol C, Baykan EC, Orem C,
Karahan B: Iron status and its relationship with lipid peroxidation in patients
with acute myocardial infarction. Acta Cardiol. 2001;56:277-281.
Baylor, College of Medicine, Lipids Online, 2001. Heterogeneity of HDL.
Retrieved on February 2006.
Beaumont C, Beris P, Beuzard Y, Brugnara C, eds. Disorders of Iron
Homeostasis, Erythrocytes, Erythropoiesis. Paris: European School of
Haematology, 2006:409e19.
Beinert H, Holm RH, Mqnck E. Iron-sulfur clusters: nature‟smodular,
multipurpose structures. Science. 1997; 277:653-59.
Beutler E. History of iron in medicine. Blood Cells Mol Dis. 2002, Nov-
Dec;29(3):297-308.
Biemond P, Van Eijk HG, Swaak AJG, Koster JF. Iron mobilization from
ferritin by superoxide derived from stimulated polymorphonuclear leukocytes:
possible mechanism in inflammatory diseases. J Clin Invest. 1984;73:1576-9.
Blessing OI, Oloruntoba F, Olarewaju MO. Plasma Glucose, Creatinine and
Urea levels in Type 2 Diabetic patients attending A Nigerian teaching hospital.
Research Journal of Medical Sciences. 2011;5(1):1-3.
Bonkovsky HL, Lambrecht RW, Shan Y. Iron as a co-morbid factor in
nonhemochromatotic liver disease. Alcohol. 2003;30:137-44.
Bonkovsky HL. Iron and the liver. 1991; Am J Med Sci 301: 32-43.
Bonsdorff VL, Lindeberg E, Sahlstedt L, Lehto J, Parkkinen J. Bleomycin -
detectable iron assay for nontransferrin bound iron in hematologic
malignancies. Clin Chem 2002;48:307-14.
Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del
Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R,Piga A,
Cnaan A: Survival and complications in patients with thalassemia major
treated with transfusion and deferoxamine. Haematologica. 2004, 89:1187-93.
REFERENCES
(203)
Bradley SJ, Gosriwatana I, Srichairatanakool S, Hider RC, Porter JB. Non-
transferrin-bound iron induced by myeloablative chemjournalapy. Br J
Haematol. 1997;99:337-43.
Brady HR, Singer GG, Acute renal failure. Lancet. 1995; 346:1533-40.
Brazzolotto X, Gaillard J, Pantopoulos K, Hentze MW, Moulis JM. Human
cytoplasmic aconitase (iron regulatory protein 1) is converted into its [3Fe-4S]
form by hydrogen peroxide in vitro but is not activated for iron-responsive
element binding. J Biol Chem.1999;274:21625-30.
Breuer W, Cabantchik ZI. A fluorescence-based one step assay for serum non-
transferrin bound iron (NTBI). Anal Biochem. , 2001;299:194-202.
Breuera W, Ermers MJ, Pootrakul P, Abramov A, Hershko C, Cabantchik ZI.
Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound
iron used for assessing chelation therapy. Blood. 2001;97:792-8.
Breuerb W, Hershko C, Cabantchik ZI. The importance of non-transferrin
bound iron in disorders of iron metabolism. Transfus Sci. 2000;23:185-92.
Breuer W, Ronson A, Slotki IN, Abramov A, Hershko C, Cabantchik ZI. The
assessment of serum nontransferrin-bound iron in chelation therapy and iron
supplementation. Blood. 2000;95:2975-82.
Bridle KR, Frazer DM, Wilkins SJ, Dixon JL, Purdie DM, Crawford DH,
Subramaniam VN, Powell LW, Anderson GJ, Ramm GA. Disrupted hepcidin
regulation in HFE-associated haemochromatosis and the liver as a regulator of
body iron homoeostasis. Lancet. 2003 Feb 22;361(9358):669-73.
Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine
in preventing complications of iron overload in patients with thalassemia
major. N Engl J Med 1994;331:567-73.
Bruick, RK. Oxygen sensing in the hypoxic response pathway: regulation of
the hypoxia-inducible transcription factor. Genes Dev. 2003;17, 2614- 23.
Buja LM, Roberts WC. Iron and the heart. Am J Med. 1971;51:209-21.
Burkitt MJ, Milne L, Raafat A. A simple, highly sensitive and improved
method for the measurement of bleomycin-detectable iron: the „catalytic iron
index‟ and its value in the assessment of iron status in haemochromatosis. Clin
Sci. 2001;100:239-47.
Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI labile plasma iron in
iron overload. Best Pract Res Clin Haematol. 2005;18:277-87.
REFERENCES
(204)
Carlson LA, Regnström J. Increase of electrophoretic mobility and of content
of soluble proteins of human plasma beta-lipoproteins by incubation of plasma
in vitro. Atherosclerosis. 1984 Dec;53(3):309-19.
Carmine TC, Evans P, Bruchelt G, Evans R, Handretinger R, Niethammer D,
et al. Presence of iron catalytic for free radical reactions in patients undergoing
chemjournalapy: implications for therapeutic management. Cancer Lett.
1995;94:219-26.
Caroline Le Lan, Olivier Loréal, Tally Cohen, Martine Ropert, Hava
Glickstein, Fabrice Lainé, Michel Pouchard, Yves Deugnier, André Le Treut,
William Breuer, Z. Ioav Cabantchik and Pierre Brissot. Redox active plasma
iron in 82Y/C282Yhemochromatosis. Blood. 2005; 105: 4527-31
Cazzola M, Huebers HA, Sayers MH, MacPhail AP, Eng M, Finch CA.
Transferrin saturation, plasma iron turnover, and transferrin uptake in normal
humans. Blood. 1985;66:935-9.
Cerriotti, F. and Cerriotti, G. Improved direct specific determination of serum
iron and total iron-binding capacity. Clin. Chem. 1980; 26, 327-31.
Chan MK, Varghese Z, Moorhead JF. Lipid abnormalities in uremia, dialysis,
and transplantation. Kidney Int. 1981 May;19(5):625-37.
Chatterjea MN and Shinde R. Text book of Medical Biochemistry. 6th
ed.
Jaypee brothers,New Delhi; 2005.
Chau L. Iron and atherosclerosis. Proceedings of the National Science
Council, Republic of China - Part B. Life Sci. 2000;24:151-5.
Clellan WM, knight DF, Karp H, Brown ww, Early detection and treatment of
renal disease in hospitalized diabetic and hypertensive patients: important
difference between practice and published guidelines. Am J Kidney Dis. 1997;
29:368 -75.
Collins KE, Collins CH, Bertran CA, Dolan J. Stainless steel surfaces in LC
systems, Part 1-corrosion and erosion. LC GC Int. 2000;13:464-70.
Cortelezzi A, Cattaneo C, Cristiani S, Duca L, Sarina B, Deliliers GL, et al.
Non-transferrin-bound iron in myelodysplastic syndromes: a marker of
ineffective erythropoiesis? Hematol J. 2000;1:153-8.
Corti MC, Guralnik JM, Salive ME, Ferrucci L, Pahor M, Wallace RB, et al.
Serum iron level, coronary artery disease, and all-cause mortality in older men
and women. Am J Cardiol. 1997;79:120-7.
Cunninghama MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of b-
thalassemia major in North America. Blood 2004; 104:34-9.
REFERENCES
(205)
Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR; Thalassemia Clinical
Research Network. Blood. 2004 Jul 1;104(1):34-9.
Cuzzocrea S, Zingarelli B, Costantino G, Szabo A, Salzman AL, Caputi AP, et
al. Beneficial effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose)
synthetase in a rat model of splanchnic artery occlusion and reperfusion. Br J
Pharmacol. 1997;121:1065-74.
Dandona P, Hussain MA, Varghese Z, Politis D, Flynn DM, Hoffbrand AV.
Insulin resistance and iron overload. Ann Clin Biochem. 1983;20:77-9.
Danesh J, Appleby P. Coronary heart disease and iron status: meta-analyses of
prospective studies. Circulation. 1999;99:852-4.
Daniel HC, Andrew JK, Sam JL, Hilary ER, The Washington manual of
medical therapeutics. 2007. Medical -780 -1.
Daphne L. van der A, Joannes JM Marx, Diederick E. Grobbee, Marjolein H.
Kamphuis, Niki A. Georgiou, J. Henny van Kats-Renaud, William Breuer, Z.
Ioav Cabantchik, Mark Roest, Hieronymus A.M. Voorbij, Yvonne T. van der
Schouw. Non-Transferrin Bound Iron and Risk of Coronary Heart Disease in
Postmenopausal women. Journal of the American Heart association, (2006);
113: 1942-9.
Daugirdas JT, Blake PG, and Ing TS. Lippincott Williams and Wilkins,
Handbook of dialysis (3rd
Edition); Philadelphia. 2001.
Davies DF, Shock NW. Age changes in glomerular filtration rate, effective
renal plasma flow and tubular excretory capacity in adult males. J Clin
Invest. 1950;29:496-504.
De Feo TM, Fargion S, Duca L, Cesana BM, Boncinelli L, Lozza P, et al.
Non-transferrin-bound iron in alcohol abusers. Alcohol Clin Exp Res.
2001;25:1494-9.
de Valk B, Addicks MA, Gosriwatana I, Lu S, Hider RC, Marx JJ. Non-
transferrin-bound iron is present in serum of hereditary haemochromatosis
heterozygotes. Eur J Clin Invest. 2000 Mar;30(3): 248-51.
Derman DP, Green A, Bothwell TH, Graham B, McNamara L, MacPhail AP,
Baynes RD.A systematic evaluation of bathophenanthroline, ferrozine and
ferene in an ICSH-based method for the measurement of serum iron. Ann Clin
Biochem. 1989 Mar;26 ( Pt 2):144-7.
Derstine JL, Murray-Kolb LE, Yu-Poth S, Hargrove RL, Kris-Etherton PM,
Beard JL: Iron status in association with cardiovascular disease risk in 3
controlled feeding studies. Am J Clin Nutr. 2003;77:56-62.
REFERENCES
(206)
Descamps LB, Witko SV, Nguyen KT, Nguyen AT, Gausson V, Mothu V, et
al. Early prediction of IgA nephropathy progression: Proteinuria and AOPP
are strong prognostic markers. Kidney Int. 2004;66:1606-12.
Detivaud L, Nemeth E, Boudjema K, Turlin B, Troadec MB, Leroyer P, et al.
Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin
levels, and hepatic function. Blood. 2005;106: 746-8.
Devlin RJ, Henry JA. "Clinical review: Major consequences of illicit drug
consumption". CritCare.2008; 12 (1):202. doi:10.1186/cc6166. PMC 2374627.
Dierk H. Endemann and Ernesto L. Schiffrin Mechanisms of Hypertension:
Cells, Hormones, and the Kidney:Endothelial Dysfunction,
JASN.2004;15:1983-92.
Dimeski G, Jones BW. Lipaemic samples: effective process for lipid reduction
using high speed centrifugation compared with ultracentrifugation. Biochem
Med (Zagreb). 2011;21(1):86-92.
Dürken M, Nielsen P, Knobel S, Finckh B, Herrnring C, Dresow B, et al. Non-
transferrin-bound iron in serum of patients receiving bone marrow transplants.
Free Rad Biol Med. 1997;22:1159-63.
Emerit J, Beaumont C, Trivin F. Iron metabolism, free radicals, and oxidative
injury. Biomed Pharmacother. 2001 Jul;55(6):333-9. Review.
Erhardt L, Herlitz J, Bossaert L, et al. (2002). "Task force on the management
of chest pain" .Eur.Heart,J. 23 (15):1153-76. doi:10.1053/euhj.2002.3194.
Erhardt LR, Sjogren A, Sawe U. Late rise in SGPT after Acute Myocardial
infarction. Acta Medica Scandinavica. 1974;196:47-51.
Eskelinen S, Haikonen M, Räisänen S. Ferene-S as the chromogen for serum
iron determinations. Scand J Clin Lab Invest. 1983 Sep;43(5):453-5.
Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik
ZI. Labile plasma iron in iron overload: redox activity and susceptibility to
chelation. Blood. 2003 Oct 1;102(7):2670-7.
Esposito BP, Breuer W, Slotki I, Cabantchik ZI. Labile iron in parenteral iron
formulations and its potential for generating plasma nontransferrin-bound iron
in dialysis patients. Eur J Clin Invest. 2002;32:42-49.
European Society of Cardiology (ESC) Committee for Practice Guidelines
(CPG). European guidelines on cardiovascular disease prevention in clinical
practice: executive summary: Fourth Joint Task Force of the European Society
of Cardiology and Other Societies on Cardiovascular Disease Prevention in
REFERENCES
(207)
Clinical Practice (Constituted by representatives of nine societies and by
invited experts). Eur Heart J. 2007 Oct;28(19):2375-414.
Evans PJ and Halliwell B. measurement of iron and Copper in biological
systems: Bleomycin and copper-phenanthroline assays, Methods. Enzymol.
1994;233:82-92.
Evans PJ, Evans R, Kovar IZ, Holton AF, Halliwell B. Bleomycin-detectable
iron in the plasma of premature and full-term neonates. FEBS Lett.
1992;303:210-12.
Evans RW, Rafique R, Zarea A, et al. Nature of non-transferrin-bound iron:
Studies on iron citrate complexes and thalassemic sera. J Biol Inorg Chem
2008;13:57-74.
Farnaud S, Evans RW. Lactoferrin--a multifunctional protein with
antimicrobial properties. Mol Immunol. 2003 Nov;40(7):395-405.
Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is
mutated in patients with hereditary haemochromatosis. Nat Genet.
1996;13:399-408.
Fernandez-Real JM, Lopez-Bermejo A, Ricart W. Iron stores, blood donation,
and insulin sensitivity and secretion. Clin Chem. 2005;51:1201-5.
Finch C. Regulators of iron balance in humans. Blood . 1994;84:1697-1702.
Franchini M. Hereditary iron overload: update on pathophysiology, diagnosis,
and treatment. Am J Hematol. 2006;81:202- 9.
Frazer DM, Wilkins SJ, Becker EM, Murphy TL, Vulpe CD, McKie AT,
Anderson GJ. A rapid decrease in the expression of DMT1 and Dcytb but not
Ireg1 or hephaestin explains the mucosal block phenomenon of iron
absorption. Gut. 2003 Mar;52(3):340-6.
Fridovich I. Oxygen toxicity: a radical explanation. J Exp Biol.
1998;201:1203-9.
Friedwald WT, Levy RI, Fredrickson D.S, Estimation of the concentration in
plasma, without use of the preparative ultracentrifuge. Clinical chem. 1972;
18:499-502.
Fytili CI, Progia EG, Panagoutsos SA, Lipoprotein abnormalities in
hemodialysis and continuous ambulatory peritoneal dialysis patients. Ren Fail.
2002;24:623-630.
Gackowski D, Kruszewski M, Jawien A, Ciecierski M, Olinski R. Further
evidence that oxidative stress may be a risk factor responsible for the
development of atherosclerosis. Free Radic Biol Med. 2001;31:542-7.
REFERENCES
(208)
Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010 May
21;5:11.
Galaris D, Mantzaris M, Amorgianiotis C. Oxidative stress and aging: the
potential role of iron. Hormones (Athens). 2008 Apr-Jun;7(2):114-22.
Ganz T. Hepcidin in iron metabolism. Curr Opin Hematol. 2004;11:251-4.
Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia
of inflammation. Blood. 2003;102(3):783-8.
Gardenghi S, Marongiu MF, Ramos P, et al. Ineffective erythropoiesis in b-
thalassemia is characterized by increased iron absorption mediated by down-
regulation of hepcidin and upregulation of ferroportin. Blood. 2007;109:5027-
35.
Genest J Jr, Marcil M, Denis M, and Yu L, High density lipoproteins in health
and in disease. J Investing Med. 1999; 47:31-42.
Gltlin D and Perricelli A, Synthesis of serum albumin, prealbumin. -
Fetoprotein, l- Antitrypsin and transferring by the human yolk sac. Nature.
1970;228:995-997.
Gopalan C, Ramshastri BV, Balasubramanium SC. Nutritive values of Indian
food. Food and their nutrient content; 1995;4:19-78.
Gosriwatana I, Loréal O, Lu S, Brissot P, Porter J, Hider RC. Quantification of
non-transferrin-bound iron in the presence of unsaturated transferrin. Anal
Biochem. 1999;273:212-20.
Goyal A, Mahaffey KW, Garg J, Nicolau JC, Hochman JS, Weaver WD,
Theroux P, Oliveira GB, Todaro TG, Mojcik CF, Armstrong PW, Granger
CB. Prognostic significance of the change in glucose level in the first 24 h
after acute myocardial infarction: results from the cardinal study. Eur Heart J.
2006; 27:1289-97.
Graham G, Bates GW, Rachmilewitz EA, Hershko C. Non-specific serum iron
in thalassaemia: quantitation and chemical reactivity. Am J Hematol.
1979;6:207-17.
Gregory LC. Lipids and lipoproteins. In: Christenson RH, Gregory LC,
Johnson LJ. Appleton and Lange's outline review clinical chemistry. New
York: McGraw Hill. 2001;27-50.
Greenspan's basic & clinical endocrinology, Mc Graw Hill, 9th
ed. 2011.
REFERENCES
(209)
Griffiths JD, Campbell LJ, Woodruff IW, Cruickshank D, Matthews JP, Hunt
D, Campbell DG, Cowling DC: Acute changes in iron metabolism following
myocardial infarction. Am J Clin Path. 1985;84:649-54.
Grootveld M, Bell JD, Halliwell B, Aruoma OI, Bomford A, Sadler PJ. Non-
transferrin bound iron in plasma or serum from patients with idiopathic
hemochromatosis. J Biol Chem. 1989;264:4417-22.
Gutman RA, Uy A, Shalhoub RJ, Wade AD, Oconnell JMB. and Recant L.
Hypertriglyceridemia in chronic non-nephrotic renal failure. Amer. J. Clinical.
Nutr. 1973;26:165-72.
Gutteridge JMC and Halliwell B. Radical promoting loosely-bound iron in
biological fuids and the bleomycin assay. Life Chem Rep. 1987;4:113-42.
Gutteridge JMC, Rowley DA and Halliwell B. Superoxide-dependent
formation of hydroxyl radicals I in the presence of iron salts. Biochem J.
1981;199:263-5.
Gutteridge JMC, Rowley DA, Griffiths E, Halliwell B. Low-molecular-weight
iron complexes and oxygen radical reactions in idiopatic
haemochromatosis.Clin Sci. 1985;68:463-7.
Gutteridge JMC, Smith A. Antioxidant protection by haemopexin of
haemstimulated lipid peroxidation. Biochem J. 1988;256:861-5.
Gutteridge JMC. Ferrous ions detected in cerebrospinal fuid by using
bleomycin and DNA damage. Clin Sci. 1992;82:315-20.
Gutteridge JMC. Iron promotors of the Fenton reaction and lipid peroxidation
can be released from haemoglobin by peroxides. FEBS Lett. 1986;201:291-5.
Hahalis G, Alexopoulos D, Kremastinos DT, Zoumbos NC. Heart failure in
beta-thalassemia syndromes: a decade of progress. Am J Med 2005;118:957-
67.
Haines TH. "Do sterols reduce proton and sodium leaks through lipid
bilayers” Prog Intern. Med. 2001;148(1):36-69:299-324.
Halliwell B, Aruoma OI, Mufti G, Bomford A. Bleomycindetectable iron in
serum from leukaemic patients before and after chemjournalapy. Therapeutic
implications for treatment with oxidant-generating drugs. FEBS Lett.
1988;241:202-4.
Halliwell B, Gutteridge JMC. Role of free radicals and catalytic metal ions in
human disease: an overview. Methods Enzymol. 1990;186:1-85.
REFERENCES
(210)
Halliwell B. Free radicals and antioxidants: a personal view. Nutr Rev 1994;
52:253-65.
Halliwell B. The role of oxygen radicals in human disease, with particular
reference to the vascular system. Haemostasis. 1993;23(suppl 1):118-26.
Han KE and Okada, S. Serum bleomycin detectable iron in patients with
thalassemia major with normal range of serum iron. Acta Med Okayama.
1995;49:117-21.
Harper HA, Rodwell VW, Mayes PA. Essential trace elements, Review of
Physiological chemistry; 1977;16:531-4.
Harrison D D-Findik E. Klein, C. Crist, J. Evans, N. Timchenko, J. Gollan,
Iron mediated regulation of liver hepcidin expression in rats and mice is
abolished by alcohol, Hepatology 2007; 46:1979-85.
Harrison P, Marwah SS, Hughes RT, Bareford D. Non-transferrin bound iron
and neutropenia after cytotoxic chemotherapy. J Clin Pathol. 1994;47:350-2.
Harrison P, Neilson JR, Marwah SS, Madden L, Bareford D, Milligan D W;
Role of non-transferrin bound iron in iron overload and liver dysfunction in
long term survivors of acute leukaemia and bone marrow transplantation. J
Clin pathol. 1996; 49:853-56.
Harrison-Findik DD, Klein E, Crist C, Evans J, Timchenko N, Gollan J. Iron-
mediated regulation of liver hepcidin expression in rats and mice is abolished
by alcohol. Hepatology. 2007;46:1979-85.
Hershko H, Graham G, Bates GW, Rachmilewitz E. Nonspecific serum iron in
thalassaemia: An abnormal serum iron fraction of potential toxicity. Br J
Haematol. 1978;40:255-63.
Hersko C. Prevalence and causes of iron deficiency anaemia. In: Beaumont C,
Beris P, Beuzard Y, Brugnara C, eds. disorders of Iron Homeostasis,
Erythrocytes, Erythropoiesis. Paris: European School of Haematology,
2006;409-19.
Hider RC. Nature of nontransferrin-bound iron. Eur J Clin Invest 2002;32:50-
4.
Higgs DR, Thein SL, Woods WG. The molecular pathology of the
thalassaemias. In: Weatherall DJ, Clegg B, eds. The thalassaemia syndromes.
4th
ed. Oxford, England: Blackwell Science, 2001;133-91.
Himmelfarb Jonathan MD, DB Morgan, Margaret E carver, RB Payne,
Relationship between serum albumin level before initiating haemodialysis and
REFERENCES
(211)
angiographic severity of coronary atherosclerosis in end-stage renal disease
patients. British Med J. 1977;2:929-32.
Hoffbrand AV. Diagnosing myocardial iron overload. Eur Heart J. 2001
Dec;22(23):2140-1.
Horner MJ, Ries LAG, Krapcho M, Neyman N, et al. (eds).. "SEER Cancer
Statistics Review, 1975-2006". Surveillance Epidemiology and End Results
(SEER). Bethesda, MD: National Cancer Institute. Retrieved November 2009.
Horwitz L, Rosenthal E. Iron-mediated cardiovascular injury. Vasc Med.
1999;4:93-9.
Hussain MK. Serum lipid profile in renal failure patients February 2008,
Essentials of Pathophsiology Concept of Altered Health States Medical.
2006;1184-6.
Ikuta K, Zak O, Aisen P. Recycling, degradation and sensitivity to the
synergistic anion of transferrin in the receptor-independent route of iron
uptake by human hepatoma (HuH-7) cells. Int J Biochem Cell Biol.
2004;36:340-52.
Inamura J, Ikuta K, Jimbo J, et al. Upregulation of hepcidin by interleukin-
1beta in human hepatoma cell lines. Hepatol Res. 2005;33:198-205.
Irshad A, Khan IU, Baloch MK and Mustafa G. Comparative Lipid profile
studies in Cardiac and Diabetic conditions. Pakistan Journal of Pharmaceutical
Sciences. 2004;17(1):25-30.
Jabbar J, Siddiqui I, Raza SQ, Baig A. To compare the total cholesterol and
HDL-cholesterol before and after ultra-centrifugation in lipemic samples. J
Pak Med Assoc. 2005 Jun;55(6):239-42.
Jackson P, Loughrey CM, Lightbody JH, McNamee PT, Young IS. Effect of
hemodialysis on total antioxidant capacity and serum antioxidants in patients
with chronic renal failure. Clin Chem. 1995;41:1135-8.
Jacobs EM, Hendriks JC, van Tits BL, Evans PJ, Breuer W, Liu DY, et al.
Results of an international round robin for the quantification of serum non-
transferrin-bound iron: Need for defining standardization and a clinically
relevant isoform. Anal Biochem. 2005;341:241-50.
Jakeman A, Thompson T, McHattie J, Lehotay DC, Sensitive method for
nontransferrin-bound iron quantification by graphite furnace atomic
absorption spectrometry, Clinical Biochemistry. 2001;34(1):43-7.
REFERENCES
(212)
Jiang R, Ma J, Ascherio A, Stampfer MJ, Willett WC, Hu FB. Dietary iron
intake and blood donations in relation to risk of type 2 diabetes in men: a
prospective cohort study. Am J Clin Nutr. 2004;79:70-5.
Jittangprasert P, Wilairat P, Pootrakul P. Comparison of colorimetry and
electrothermal atomic absorption spectroscopy for the quantification of non-
transferrin bound iron in human sera. Southeast Asian J Trop Med Public
Health. 2004;35:1039-44.
Johonson AM, Rolfs EM, and Silverman LM ,(Proteins) In Tietz-Textbook of
Clinical Chemistry (Eds) Burtis A. B. and Ashwood E R (3rd
edition)
Philadelphia, 1999; (1) :482-90.
Joki N, Hase H, Ishikawa H, Fukazawa C, Nakamura R, Imamura Y, Tanaka
Y,Saijyo T, Fukazawa M, Yamaguchi T. Coronary artery disease as a
definitive risk factor of short-term outcome after starting hemodialysis in
diabetic renal failure patients. Clin Nephrol. 2001 Feb;55(2):109-14.
Judykay T. Nutrition for reducing urea and creatinine in the blood. Diabetes
Care. 2007;27:2191-2.
Kakhlon O, Cabantchik ZI. The labile iron pool: characterization,
measurement, and participation in cellular processes. Free Rad Biol Med.
2002;33:1037-46.
Kaplan A, Lavernel LS. Enzymes, In: Clinical Chemistry Interpretation and
Techniques, 2nd ed. Lea and Febiger, Philadelphia, (1983):173-217.
Kaplan LA. Carbohydrates and Metabolite, In: Clinical chemistry Theory,
analysis and correlation. Kaplan LA and Pesce AJ. Eds. CV. Mosby, Toronto,
1984:1032-40.
Kaplan LA, Pesce AJ. Hemoglobin porphyrin and iron metabolism, Clinical
chemistry and correlation. 1989;2:445-8.
Karnon J, Zeuner D, Brown J, Ades AE, Wonke B, Modell B. Lifetime
treatment costs of beta-thalassaemia major. Clin Lab Haematol. 1999
Dec;21(6):377-85.
Kartikasari AE, Georgiou NA, Visseren FL, van Kats-Renaud H, van Asbeck
BS, Marx JJ. Intracellular labile iron modulates adhesion of human monocytes
to human endothelial cells. Arterioscler Thromb Vasc Biol. 2004;24:2257-62.
Knight JA. Free Radicals, Antioxidants, Aging and Disease. AACC Press,
1999, Washington, DC.
Knovich MA, Storey J, Coffman L, Torti S, Torti F. Ferritin for the clinician.
Blood Reviews. 2008;23(3):95-104.
REFERENCES
(213)
Knuiman MW, Divitini ML, Olynyk JK, Cullen DJ, Bartholomew HC. Serum
ferritin and cardiovascular disease: a 17- year follow-up study in Busselton,
Western Australia. Am J Epidemiol. 2003;158:144-9.
Kohgo Y, Ikuta K, Ohtake T, Torimoto Y, Kato J. Body iron metabolism and
pathophysiology of iron overload. Int J Hematol. 2008 Jul;88(1):7-15
Kolb AM, Smit NP, Lentz-Ljuboje R, Osanto S, van Pelt J. Non-transferrin
bound iron measurement is influenced by chelator concentration. Anal
Biochem. 2009;385:13-9.
Koo SW, Casper KA, Otto KB, Gira AK, Swerlick RA. Iron chelators inhibit
VCAM-1 expression in human dermal microvascular endothelial cells. J
Invest Dermatol. 2003;120:871-9.
Koorts AM, Viljoen M. Ferritin and ferritin isoforms I: structurefunction
relationships, synthesis, degradation and secretion. Arch Physiol Biochem.
2007;113:30-54.
Koppenol W.H. "The Haber-Weiss cycle - 70 years later". Redox Report.
2001;6:229-34.
Kosuge M, Kimura K, Ishikawa T, Ebina T, Hibi K, Tsukahara K, Kanna
M,Iwahashi N, Okuda J, Nozawa N, Ozaki H, Yano H, Nakati T, Kusama I,
Umemura S.Differences between men and women in terms of clinical features
of ST-segment elevation acute myocardial infarction. Circ J. 2006
Mar;70(3):222-6.
Kruszewski M. Labile iron pool: the main determinant of cellular response to
oxidative stress. Mutat Research. 2003;531:81-92.
Kruszewski M. The role of labile iron pool in cardiovascular diseases. Acta
Biochemical Polonica. 2004;51(2):471-80.
Kutty K, Mahender SK. Kochar's Concise Textbook of Medicine, 5th
ed,
Lippincott Williams and Wilkins,California;2003.
Le Lan C, Loréal O, Cohen T, Ropert M, Glickstein H, Lainé F, et al. Redox
active plasma iron in C282Y/C282Y hemochromatosis. Blood.
2005;105:4527-31.
Leake D, Rankin S. The oxidative modi. cation of low-density lipoproteins by
macrophages. Biochem J. 1990;270:741-8.
Lebowitz HE. Type 2 Diabetes: An Overview. Clin. Chem. 1999;45:1339-45.
REFERENCES
(214)
Lee DH, Folsom AR, Jacobs DRJ. Iron, zinc, and alcohol consumption and
mortality from cardiovascular diseases: the Iowa Women‟s Health Study. Am
J Clin Nutr. 2005;81:787-91.
Lee DH, Liu DY, Jacobs DR Jr, Shin HR, Song K, Lee IK, Kim B, Hider RC.
Common presence of non-transferrin-bound iron among patients with type 2
diabetes. Diabetes Care. 2006 May;29(5):1090-5.
Lele S, Shah S, McCullough PA, Rajapurkar M. Serum catalytic iron as a
novel biomarker of vascular injury in acute coronary syndromes.
EuroIntervention. 2009 Aug;5(3):336-42.
Leonardo AS, Cristiana C, Laura Z, Alessandra M, and Sergio D.
Abnormalities of Glucose Metabolism in Patients With Early Renal Failure. J
Diabetes. 2002;51:1226-36.
Lernmark A. Type 1 Diabetes. Clin. Chem. 1999;45(8Pt2):1331-38.
Levey AS , Bosch JP , Lewis JB , Greene T , Rogers N , Roth D, A more
accurate method to estimate GFR from serum creatinine: anew prediction
equation . Modification of Diet in Renal Disease Study Group. Ann intern
Med. 1999;130:461-71.
Lin JL, Lin Tan DT, Hsu KH, Yu CC. Environmental lead exposure and
progression of chronic renal diseases in patients without diabetes. N Engl J
Med. 2003;348:277-86.
Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline
in renal function with age. J Am Geriatr Soc. 1985;33: 278-85.
Liochev SI, Fridovich I. The relative importance of HO. and ONOO- in
mediating the toxicity of O•. Free Radic Biol Med. 1999;26:777-8.
Liu P, Olivieri N. Iron overload cardiomyopathies: new insights into an old
disease. Cardiovasc Drugs Ther. 1994;8:101-10.
Liuzzi JP, Aydemir F, Nam H, Knutson MD, Cousins RJ. Zip14 (Slc39a14)
mediates non-transferrin-bound iron uptake into cells Proc Natl Acad Sci
USA. 2006;103:13612-7.
Loken MR, Shah VO, Dattilio KL, Civin CI. Flow cytometric analysis of
human bone marrow. II. Normal B lymphocyte development. Blood.
1987;70:1316-24.
Longo-Mbenza B, Luila EL, Mbete P, Vita EK, Hyperuricemia a risk factor of
stroke and coronary heart disease among Africans. Int J Cardiol. 1999;71:17-
22.
REFERENCES
(215)
Loreal O, Gosriwatana I, Guyader D, Porter J, Brissot P, Hider RC.
Determination of non-transferrin-bound iron in genetic hemochromatosis
using a new HPLC-based method. J Hepatol. 2000;32:727-33.
Lovstad RA. Interaction of serum albumin with the Fe (III)-citrate complex.
Int J Biochem. 1993;25:1015-7.
Mahesh S, Ginzburg Y, Verma A. Iron overload in myelodysplastic
syndromes, Leuk Lymphoma. 2008;49:427-38.
Majumdar A and Wheeler DC, Lipid abnormalities in renal disease. J R Soc
Med. 2000;93:178-82.
Mallinson T. Myocardial Infarction. Focus on First Aid. 2010;15(15)
Retrieved 2010-06-08.
Marwah SS, Blann A, Harrison P, Lumley MA, Wright J, McDowell J,
Phillips JD,Rea C, Bareford D. Increased non-transferrin bound iron in
plasma-depleted SAG-M red blood cell units. Vox Sang. 2002 Apr;82(3):122-
6.
May PM, Williams DR, Computer simulation of chelation therapy. Plasma
mobilizing index as a replacement for effective stability constant. FEBS Lett.
1977;78:134-8.
McKie AT, Latunde-Dada GO, Miret S, et al. Molecular evidence for the role
of a ferric reductase in iron transport. Biochem Soc Trans. 2002;30:722-4.
Mendler MH, Turlin B, Moirand R, Jouanolle AM, Sapey T, Guyader D, et al.
Insulin resistance-associated hepatic iron overload. Gastroenterology.
1999;117:1155-63.
Meyers DG. The iron hypothesis: does iron play a role in atherosclerosis?
Transfusion. 2000;40:1023-9.
Michael JF. Role of sodium in hemodialysis. Kidney International USA.
2000;58,Suppl.76,72-8
Mingwei Q, Michael L, John WE. Transition Metals Bind to Glycated protein
forming redox active “Glycochelates”: Implications for the pathogenesis of
certain Diabetic complications. Biochemical and Biophysical research
communication. 1998;250:385-9.
Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the
UK: data from the UK Thalassaemia Register. Lancet 2000;355:2051-2.
Mohan S, Kalia K, Mannari J. Diabetic nephropathy and associated risk
factors for renal deterioration. Int J diabetes Dev Ctries. 2011;32:52-9.
REFERENCES
(216)
Moss DW, Henderson AK, Clinical enzymology, In Tietz textbook of clinical
chemistry. 3rd
edition, Burtis CA and Ashwood ER, Eds .WB Saunders,
Philadelphia. 1999;617-721.
Muhlestein JB. Cardiac abnormalities in hemochromatosis. In: Barton JC,
Edwards CQ, eds. Hemochromatosis: genetics, pathophysiology, diagnosis,
and treatment. Barton JC, Edwards CQ, eds. Cambridge: Cambridge
University Press; 2000;297-310.
Muncie HL Jr, Campbell J. Alpha and beta thalassemia. Am Fam Physician.
2009 Aug 15;80(4):339-44. Review.
Murry RL. Non Protein Nitrogenous Compounds, In: Cilinical chemistry
theory, Analysis and correlation. Kaplan LA and Pesce AJ. Eds. CV. Mosby,
Toronto, (1984): 1230-68.
Nankivell BJ, Boadle RA, Harris DCH. Iron accumulation in human chronic
renal disease. Am J Kidney Dis. 1992;20:580-4.
Newman and Price CP. Renal function and nitrogen metabolites, In: Tietz
textbook of clinical chemistry. 3rd
edition, Burtis CA and Ashwood ER, Eds.
WB Saunders, Philadelphia. 1991;1204-64.
Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer
G. Long-term survival in patients with hereditary hemochromatosis.
Gastroenterology 1996;110:1107-19
Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ,
Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic
patients with primary hemochromatosis. N Engl J Med 1985;313:1256-62.
Nilsson UA, Bassen M, Sävman K, Kjellmer I. A simple and rapid method for
the determination of "free" iron in biological fluids. Free Radic Res.
2002;36:677-84.
Nolan CR, Anderson RJ, Hospital-acquired acute renal failure. Jam Soc
Nephrol. 1998;9:710-8.
Old JM, Olivieri NF, Thein SL. Diagnosis and management of thalassaemia.
In: Weatherall DJ, Clegg B, eds. The thalassaemia syndromes.4th ed. Oxford,
England: Blackwell Science, 2001:630-85.
Olivieri NF, Brittenham GM, Iron chelation therapy and treatment of
thalassemia. Blood. 1997;89:739-61.
Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated
patients with homozygous beta-thalassemia. N Engl J Med 1994;331:574-8.
REFERENCES
(217)
Olivieri NF. The beta-thalassemias. N Engl J Med 1999;341:99-109.
Ostlund RE, Racette, SB, and Stenson WF, "Inhibition of Cholesterol
absorption by phytosterols-replete wheat germ Compared with phytosterols-
depleted wheat germ". Am J Clin Nutr. 2003;77(6):1385-6.
Oudit GY, Trivieri MG, Khaper N, Husain T, Wilson GJ, Liu P, et al. Taurine
supplementation reduces oxidative stress and improves cardiovascular
function in an iron-overload murine model. Circulation. 2004;109:1877-85.
Paffetti P, Perrone S, Longini M, Ferrari A, Tanganelli D, Marzocchi B, et al.
Non-protein-bound iron detection in small samples of biological fluids and
tissues. Biol Trace Elem Res. 2006;112:221-32.
Pagana and Pagana. Moshby‟s manual of diagnostic and laboratory tests. 3rd
ed. Moshby Elsevier, USA, 2006.
Pai B, Pai MP, Depczynski J, McQuade CR, Mercier RC. Nontransferrin-
bound iron is associated with enhanced Staphylococcus aureus growth in
hemodialysis patients receiving intravenous iron sucrose. Am. J. Nephrol.
2006;26:304-9.
Papanikolaou G, Pantopoulos K. Iron metabolism and toxicity. Toxicol Appl
Pharmacol. 2005 Jan 15;202(2):199-211. Review.
Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial
peptide synthesized in the liver. J Biol Chem. 2001;276:7806-10.
Pietrangelo A. Hemochromatosis: an endocrine liver disease. Hepatology.
2007;46:1291-301.
Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and
treatment. Gastroenterology. 2010 Aug;139(2):393-408.
Pietrangelo A. Hereditary hemochromatosis—a new look at an old disease. N
Engl J Med. 2004;350:2383-97.
Ponka P. Tissue-specific regulation of iron metabolism and heme synthesis:
distinct control mechanisms in erythroid cells. Blood. 1997;89:1-25.
Pootrakul P, Breuer W, Sametband M, Sirankapracha P, Hershko C,
Cabantchik ZI. Labile plasma iron (LPI) as an indicator of chelatable plasma
redox activity in iron-overloaded b-thalassemia/HbE patients treated with an
oral chelator. Blood. 2004;104:1504-10.
Pootrakul P, Sirankapracha P, Sankote J, Kachintorn U, Maungsub W, Sriphen
K, et al. Clinical trial of deferiprone iron chelation therapy in beta-
REFERENCES
(218)
thalassaemia/haemoglobin E patients in Thailand. Br J Haematol.
2003;122:305-10.
Porter JB, Abeysinghe RD, Marshall L, Hider RC, Singh S. Kinetics of
removal and reappearance of nontransferrin- bound plasma iron with
deferoxamine therapy. Blood. 1996;88:705-13.
Porter JB. Pathophysiology of transfusional iron overload: Contrasting
patterns in thalassemia major and sickle cell disease Hemoglobin
2009;33:S37- S45.
Prabhu R, Prabhu V, Prabhu RS. Iron over load in beta thalassemia. J Biosci
Tech. 2009;1(1):20-31.
Prakash M, Upadhya S, Prabhu R. Serum non-transferrin bound iron in
hemodialysis patients not receiving intravenous iron. Clin Chim Acta. 2005
Oct;360(1-2):194-8.
Praticó D, Pasin M, Barry OP, Ghiselli A, Sabatino G, Iuliano L,et al. Iron-
dependent human platelet activation and hydroxyl radical formation:
involvement of protein kinase C. Circulation. 1999;99:3118-24.
Prus E, Fibach E. Uptake of non-transferrin iron by erythroid cells. Anemia.
2011;Article ID 945289, 8 pages.
Puppo A, Halliwell B. Formation of hydroxyl radicals from hydrogen peroxide
in the presence of iron: is haemoglobin a biological Fenton catalyst? Biochem
J. 1988;249:185-90.
Qian M, Liu M, Eaton JW. Transition Metals Bind to Glycated Proteins
Forming Redox Active “Glycochelates”: Implications for the Pathogenesis of
Certain Diabetic Complications. Biochemical and biophysical research
communications. 1998;250:385-89.
Ramakrishnan U, Kuklina E, Stein AD: Iron stores and cardiovascular disease
risk factors in women of reproductive age in the United States. Am J Clin
Nutr. 2002;76:1256-60.
Redmon JB, Pyzdrowski KL, Robertson RP. No effect of deferoxamine
therapy on glucose homeostasis and insulin secretion in individuals with
NIDDM and elevated serum ferritin. Diabetes. 1993;42:544-9.
Richardson DR, Ponka P. The molecular mechanisms of the metabolism
andtransport of iron in normal and neoplastic cells. Biochim Biophys Acta.
1997 Mar 14;1331(1):1-40.
Robert W. Schrier, Manual of Nephrology. Medical. 2004:350-52.
REFERENCES
(219)
Roche M, Rondeau P, Singh N, Tarnus E, Bourdon E. The antioxidant
properties of serum albumin. Federation of European Biochemical Societies
Letters. 2008;582:1783-7.
Rösen P, Nawroth PP, King G, Möller W, Tritschler HJ, Packer L. The role of
oxidative stress in the onset and progression of diabetes and its complications:
a summary of a Congress Series sponsored by UNESCO-MCBN, the
American Diabetes Association and the German Diabetes Society. Diabetes
Metab Res Rev. 2001May-Jun;17(3):189-212.
Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med.
1999;340:115-26.
Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW. The effect of age on
creatinine clearance in men: a cross-sectional and longitudinal study. J
Gerontol. 1976;31:155-63.
Roy CN, Enns CA. Iron homeostasis: new tales from the crypt. Blood.
2000;96:4020-7.
Rund D and Rachmilewitz E. β-Thalassemia. N Engl J Med. 2005;353:1135-7.
Ryter SW, Tyrrell RM. The heme synthesis and degradation pathways: role in
oxidant sensitivity. Heme oxygenase has both pro- and antioxidant properties.
Free Radical Biol. Med. 2000;28:289-309.
Sahlstedt L, Ebeling F, von Bonsdorff L, Parkkinen J, Ruutu T. Non-
transferrin-bound iron during allogeneic stem cell transplantation. Br J
Haematol. 2001;113:836-8.
Sahlstedt L, Von Bonsdorff L, Ebeling F, Parkkinen J, Juvonen E and Ruutu
T. Non-transferrin-bound iron in haematological patients during chemotherapy
and conditioning for autologous stem cell transplantation. European Journal of
Haematology. 2009;83:455-9. doi: 10.1111/j.1600-0609.2009.01310.x.
Salvemini D, Wang ZQ, Bourdon DM, Stern MK, Currie MG, Manning PT.
Evidence of peroxynitrite involvement in the carrageenan-induced rat paw
edema. Eur J Pharmacol. 1996;303:217-20.
Sargent PJ, Farnaud S, Evans RW. Structure/function overview of proteins
involved in iron storage and transport. Curr Med Chem. 2005;12:2683-93.
Sasaki K, Ikuta K, Tanaka H, Ohtake T, Torimoto Y, Fujiya M, et al.
Improved quantification for non-transferrin-bound iron measurement using
high-performance liquid chromatography by reducing iron contamination. Mol
Med Report. 2011;4:913-8.
REFERENCES
(220)
Satyanarayana U and Chakrapani U. Biochemistry. 3rd
ed. Uppala author-
publisher interlink, Vijaywada, 2009.
Schafer AI, Cheron RG, Dluhy R, Cooper B, Gleason RE, Soeldner JS, et al.
Clinical consequences of acquired transfusional iron overload in adults. N
Engl J Med. 1981;304:319-24.
Schaller Georg, Barbara Scheiber-Mojdehkar, Michaelwolzt, Heidi puttinger,
Friedrich mittermayer, Intravenous iron increases labile serum iron but does
not impair forearm blood flow reactivity in dialysis patients November,
Kidney Int. 2005;68:2814-22.
Schellhammer PF, Engle MA, Hagstrom JW. Histochemical studies of the
myocardium and conduction system in acquired iron-storage disease.
Circulation. 1967;35:631-7.
Schumann G, IFCC Primary reference procedures for the measurement of
catalytic activity of enzymes at 37˚C. J Clin Chem Lab med. 2002; 40:725-
733.
Sempos CT, Looker AC, Gillum RE, Mc- Gee DL, Vuong CV, Johnson CL.
Serum ferritin and death from all causes and cardiovascular disease: the
NHANES II Mortality Study. Ann Epidemiol. 2000;10:441-8.
Shah SV, Baliga R, Rajapurkar M, Fonseca VA. Oxidants in chronic kidney
disease. J Am Soc Nephrol. 2007;18:16-28.
Shah SV. Oxidants and iron in chronic kidney disease. Kidney Int Suppl.
2004;91:50-5.
Sharma M, Gohil NK. Interaction of azotobactin with blocking and mobilizing
agents in NTBI assay. Mol Biosyst. 2010;6:1941-6.
Sharma M, Saxena R, Gohil NK. Fluorescence assay of non-transferrin-bound
iron in thalassemic sera using bacterial siderophore. Anal Biochem.
2009;394:186-91.
Shetty JK, Prakash M, Ibrahim MS. Relationship between free Iron and
glycated hemoglobin in uncontrolled type 2 diabetes patients associated with
complications. Indian J Clin Biochem. 2008;23(1):67-70.
Shoback, edited by David G. Gardner, Dolores. Greenspan's basic & clinical
endocrinology. 9th
ed. New York: McGraw-Hill Medical; 2011. Chapter
17. ISBN 0-07-162243-8.
Silva AM, Hider RC. Influence of non-enzymatic post-translation
modifications on the ability of human serum albumin to bind iron implications
REFERENCES
(221)
for non-transferrin- bound iron speciation. Biochim Biophys
Acta.2009;1794:1449-58.
Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a
review. Diabetologia. 2001;44:129-46.
Singh S, Hider RC, Porter JB. A direct method for quantification of non-
transferin-bound iron. Anal Biochem. 1990;186:320-3.
Skutches C, Holroyde C, Myers R. et al. Plasma acetate turnover and
oxidation. J Clin Invest. 1979;64(3):708-13.
Smith LL. Another cholesterol hypothesis: cholesterol as antioxidant. Free
Radical. Biol Med. 1991;11(1):47-61.
Smith HW. The Kidney: Structure and Function in Health and Disease, p. 57.
Oxford University Press, New York; 1951.
Steptoe A, Kivimäki M. Stress and cardiovascular disease. Nat Rev Cardiol.
2012 Apr 3;9(6):360-70. doi: 10.1038/nrcardio.2012.45. Review.
Stewart, W.B., Yuile, C.L., Claiborne, H.A., Snowman, R.T., Whipple, G.H.
Radioiron absorption in anemic dogs; fluctuations in the mucosal block and
evidence for a gradient of absorption in the gastrointestinal tract. J. Exp. Med.
1950;92,375- 82.
Stuart KA, Anderson GJ, Frazer DM, et al. Duodenal expression of iron
transport molecules in untreated haemochromatosis subjects. Gut.
2003;52(7):953-9.
Sulieman M, Asleh R, Cabantchik ZI, Breuer W, Aronson D, Suleiman A,
Miller-Lotan R, Hammerman H, Levy AP. Serum chelatable redox-active iron
is an independent predictor of mortality after myocardial infarction in
individuals with diabetes. Diabetes Care. 2004 Nov;27(11):2730-2.
Sullivan JL: Iron and the sex difference in heart disease risk. Lancet.
1981;1:1293-4.
Suryawanshi NP, Bhutey AK, Nagdeote AN, Jadhav AA and Manoorkar GS.
Study of Lipid peroxide and Lipid profile in Diabetes Mellitus. Indian J Clin
Biochem. 2006;21(1):126-30.
Takahashi S, Warabayasi Y, Nakai T, Sakai J and Yamamoto T, Rabbit very
low density lipoprotein receptor: a low density lipoprotein receptor-like
protein with distinct ligand specificity. Proc Natl Acad Sci USA. 1992;89:
9252-6.
Telfer P, Coen PG, Christou S, Hadjigavriel M, Kolnakou A, Pangalou E,
Pavlides N, Psiloines M, Simamonian K, Skordos G, Sitarou M,Angastiniotis
REFERENCES
(222)
M: Survival of medically treated thalassemia patients in Cyprus. Trends and
risk factors over the period 1980-2004. Haematologica. 2006;91:1187-92.
Termini J. Hydroperoxide-induced DNA damage and mutations. Mutat Res.
2000;450:107-24.
Terres W, Beil U, Riemann B, and Tiede S, Bleifeld W, Low dose fish oil in
primary hypertriglyceridemia. A randomized placebo-controlled study in
German. Festschrift für Cardiologic. 1991;80(1):20-4.
Tietz Text book of clinical chemistry. Lipid, Lipoprotein and Apolipoproteins.
3rd
ed. Burtis CA and Ashwood ER, Eds .WB Saunders, Philadelphia; 1999.
Tietz N.W. Fundamentals of Clinical Chemistry. 5th
ed, Philadelphia,
W.B.Saunders; 1976.
Teitz Text book of Clinical Chemistry and Molecular Diagnostics, 4th
edition
Elsevier Saunders, St. Louis, Missouri ; 2006.
Trinder D, Fox C, Vautier G, Olynyk JK. Molecular pathogenesis of iron
overload. Gut. 2002;51:290-5.
Tsaltas TT and Friedman EA. Plasma lipid studies in uremic patients during
hemodialysis. Amer. J Clin Nutr.1968;21:430-5.
Turk HM, Sevinc A, Camci C, Cigli A, Buyukberber S, Savli H, Bayraktar N.
Plasma lipid peroxidation products and antioxidant enzyme activities in
patients with type 2 diabetes mellitus. Acta Diabetol. 2002 Sep;39(3):117-22.
Valensi P, Lorgis L, Cottin Y. Prevalence, incidence, predictive factors and
prognosis of silent myocardial infarction: a review of the literature. Arch
Cardiovasc Dis. 2011 Mar;104(3):178-88.
van der ADL, Marx JJ, Grobbee DE, Kamphuis MH, Georgiou NA, van Kats-
Renaud JH, Breuer W, Cabantchik ZI, Roest M, Voorbij HA, van der Schouw
YT. Non-transferrin-bound iron and risk of coronary heart disease in
postmenopausal women. Circulation. 2006 Apr 25;113(16):1942-9. Epub 2006
Apr 17. Erratum in: Circulation. 2006 May 30;113(21):e784.
van der ADL, Peeters PH, Grobbee DE, Marx JJ, van der Schouw YT. Dietary
haem iron and coronary heart disease in women. Eur Heart J. 2005;26:257-62.
van der Heul C, van Eijk HG, Wiltink WF, Leijnse B. The binding of iron to
transferrin and to other serum components at different degrees of saturation
with iron, Clin Chim Acta. 1972;38:347-53.
Van Wyck DB. Labile iron: manifestations and clinical implications. J Am
Soc Nephrol. 2004 Dec;15 Suppl2:S107-11.
REFERENCES
(223)
Vasudevan DM, Sreekumari S, Kannan Vaidyanathan. Mineral Metabolism
and Abnormalities. Text book of biochemistry for Medical students, 6th
ed.
Jaypee Brothers Medical Publishers (P) Ltd. New Delhi; 2011.
Vasudevan DM, Sreekumari S. Text book of Biochemistry for Medical
students. 3th
ed. Jaypee Brothers Medical Publishers (P) Ltd. New Delhi; 2001.
Victoria SL and Joel DK, Protein metabolism in patients with chronic renal
failure: Role of uraemia and dialysis Division of Nephrology, Department of
Medicine, University of Iowa College of Medicine, Torrance, and the UCLA
Schools of Medicine and Public Health, Los Angeles, California. USA,
Kidney International. 2000;58:1-10.
Vincent CJ. Laboratory tests and diagnostic procedures. 5th
ed. Julie
Alexander, New Jersey; 2000.
von Bonsdorff L, Lindeberg E, Sahlstedt L, Lehto J, Parkkinen J. Bleomycin-
detectable iron assay for non-transferrin-bound iron in hematologic
malignancies. Clin Chem. 2002;48:307-14.
Voogd A, Sluiter W, Koster JF. The increased susceptibility to hydrogen
peroxide of the (post-) ischemic rat heart is associated with the magnitude of
the low molecular weight iron pool. Free Radic Biol Med. 1994;16:453-8.
Walter GO. Iron deficiency anemia. Lecture in hematology,1974:493-502.
Washington DC. Living with kidney disease: a patient manual fifth edition.
September, 2002;13-15.
Washington DC. Living kidney failure. Superintendent of Documents
Government Printing Office 20402; (2002):783-3238.
Weatherall DJ, Clegg JB: The thalassaemia syndromes 4th
edition. Oxford,
England: Blackwell Science; 2001.
Weijl NI, Elsendoorn TJ, Moison RM, Lentjes EG, Brand R, Berger HM,
Osanto S. Non-protein bound iron release during chemotherapy in cancer
patients. Clin Sci(Lond). 2004 May;106(5):475-84.
West IC. Radicals and Oxidative stress in Diabetes. Diabet. Med.
2000;17:171-80.
William j Marshall, Clinical biochemistry (Acute renal failure in critically ill
patients: A multinational, multicenter study. Article \Pub med \ISI \chemport.
JAMA (2004); 204:813-18.
Williams textbook of endocrinology, 12th
ed. Philadelphia: Elsevier/Saunders;
2011. ISBN 978-1-4377-0324-5.
REFERENCES
(224)
World Health Organization (2008). The Global Burden of Disease: 2004
Update. Geneva: World Health Organization. ISBN 92-4-156371-0
Yen AW, Fancher TL, Bowlus CL. Revisiting hereditary hemochromatosis:
current concepts and progress. Am J Med. 2006;119:391-9.
Zhang D, Okada S, Kawabata T, Yasuda T. An improved simple colorimetric
method for quantification of non-transferrin-bound iron in serum. Biochem
Mol Biol Int. 1995;35:635-41.
Zhang WJ, Frei B. Intracellular metal ion chelators inhibit TNF alpha-induced
SP-1 activation and adhesion molecule expression in human aortic endothelial
cells. Free Radic Biol Med. 2003;34:674-82.